MA52148A - Peptides chimères pour administration d'antisens - Google Patents
Peptides chimères pour administration d'antisensInfo
- Publication number
- MA52148A MA52148A MA052148A MA52148A MA52148A MA 52148 A MA52148 A MA 52148A MA 052148 A MA052148 A MA 052148A MA 52148 A MA52148 A MA 52148A MA 52148 A MA52148 A MA 52148A
- Authority
- MA
- Morocco
- Prior art keywords
- chimères
- antisens
- peptides
- administration
- peptides chimères
- Prior art date
Links
- 241000251204 Chimaeridae Species 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644202P | 2018-03-16 | 2018-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52148A true MA52148A (fr) | 2021-01-20 |
Family
ID=67908050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052148A MA52148A (fr) | 2018-03-16 | 2019-03-15 | Peptides chimères pour administration d'antisens |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12370261B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3765030A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7596148B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA52148A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202002990A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019178479A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| US20250228954A1 (en) * | 2020-01-24 | 2025-07-17 | Sarepta Therapeutics, Inc. | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning |
| CA3211038A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| WO2026080471A2 (en) | 2024-10-07 | 2026-04-16 | Flagship Pioneering Innovations Vi, Llc | Compositions of trem conjugates and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5752601A (en) | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| AU2006267051B2 (en) | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| AU2011367230B2 (en) | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP2755690B1 (en) | 2011-08-04 | 2020-04-01 | Merck Sharp & Dohme B.V. | Kisspeptide-pentasaccharide conjugates |
| US9512073B2 (en) | 2011-10-27 | 2016-12-06 | Massachusetts Institute Of Technology | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| US10111962B2 (en) | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| WO2014124952A1 (en) | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| EP3760720A1 (en) | 2013-03-14 | 2021-01-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| HK1220154A1 (zh) * | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| WO2015038933A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Phosphorylated akt-specific capture agents, compositions, and methods of using and making |
| CN113105559A (zh) * | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| GB201421379D0 (en) | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
| WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
| WO2019079386A1 (en) * | 2017-10-17 | 2019-04-25 | Sarepta Therapeutics, Inc. | CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION |
| EP3829597A4 (en) * | 2018-07-30 | 2022-05-18 | Sarepta Therapeutics, Inc. | TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION |
-
2019
- 2019-03-15 EP EP19767585.3A patent/EP3765030A4/en active Pending
- 2019-03-15 MA MA052148A patent/MA52148A/fr unknown
- 2019-03-15 TW TW108108833A patent/TW202002990A/zh unknown
- 2019-03-15 JP JP2020549641A patent/JP7596148B2/ja active Active
- 2019-03-15 WO PCT/US2019/022475 patent/WO2019178479A1/en not_active Ceased
- 2019-03-15 US US16/981,145 patent/US12370261B2/en active Active
-
2024
- 2024-09-17 JP JP2024159928A patent/JP2024163336A/ja active Pending
-
2025
- 2025-06-10 US US19/233,984 patent/US20250367306A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12370261B2 (en) | 2025-07-29 |
| EP3765030A1 (en) | 2021-01-20 |
| JP7596148B2 (ja) | 2024-12-09 |
| WO2019178479A1 (en) | 2019-09-19 |
| US20250367306A1 (en) | 2025-12-04 |
| EP3765030A4 (en) | 2022-01-26 |
| JP2024163336A (ja) | 2024-11-21 |
| US20210260206A1 (en) | 2021-08-26 |
| JP2021518361A (ja) | 2021-08-02 |
| TW202002990A (zh) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3924799A4 (en) | GEO REFERENCE POINTS FOR UAV NAVIGATION | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3621656A4 (en) | EYE MEDICINAL DELIVERY FORMULATION | |
| EP3640237A4 (en) | LIPID MEMBRANE STRUCTURE FOR ADMINISTRATION IN SIRNA CELLS | |
| EP3446726A4 (en) | MUNDPFLEGESPUTUMSAUGROHR | |
| EP3810177A4 (en) | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 | |
| EP3328429A4 (en) | PEPTIDES AND ANTIBODIES FOR THE DISPOSAL OF BIOFILMS | |
| IL282773A (en) | Edaravone suspension for oral administration | |
| EP3256149A4 (en) | FORMULATION FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES | |
| EP3810196A4 (en) | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | |
| EP3383418A4 (en) | SLC45A2 PEPTIDES FOR IMMUNOTHERAPY | |
| EP3645039A4 (en) | USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP3836866A4 (en) | SYSTEMS FOR ENTERIC DELIVERY OF THERAPEUTICS | |
| EP3810178A4 (en) | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 | |
| EP3523274A4 (en) | FORMULATIONS FOR THE ADMINISTRATION OF EFLORNITHIN | |
| EP3810176A4 (en) | CYCLIC POLYPEPTIDES TO INHIBIT PCSK9 | |
| MA53375A (fr) | Dispositifs d'administration pour l'administration de médicaments | |
| EP3509573A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | |
| EP3668991A4 (en) | NANOCARRIERS FOR DELIVERY OF ACTIVE SUBSTANCES | |
| EP3773221A4 (en) | TREATMENT OF HYDROCEPHALUS | |
| EP3716966A4 (en) | ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA | |
| EP3621597A4 (en) | BIODEGRADABLE MICROPARTICLE FOR THE DELAYED RELEASE OF ANTI-ANGIOGENIC PEPTIDE | |
| MA53238A (fr) | Formules d'ag10 | |
| EP3958972A4 (en) | THERAPEUTIC DRUG FOR DYSKINESIA |